Aquatic Capital Management LLC Incyte Corp Transaction History

Aquatic Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$51.18 - $63.75 $281,490 - $350,625	-5,500 Reduced 13.55%	35,100 $2.13 Million
Q1 2024 May 15, 2024	BUY	$56.55 - $66.59 $2.3 Million - $2.7 Million	40,600 New	40,600 $2.31 Million
Q3 2023 Nov 14, 2023	BUY	$57.77 - $65.93 $2.45 Million - $2.8 Million	42,400 Added 67.73%	105,000 $6.07 Million
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $1.33 Million - $1.65 Million	21,800 Added 53.43%	62,600 $3.9 Million
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $2.87 Million - $3.51 Million	40,800 New	40,800 $2.95 Million
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $1.22 Million - $1.52 Million	18,400 New	18,400 $1.23 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Aquatic Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aquatic Capital Management LLC with notifications on news.